Gyre Therapeutics
Update in progressGYRE (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Gyre Therapeutics, Inc. is a San Diego–based pharmaceutical company focused on small‑molecule therapies for organ fibrosis. Its pipeline includes ETUARY (Pirfenidone), approved for idiopathic pulmonary fibrosis; and F351 (Hydronidone), in Phase 3 for CHB‑associated liver fibrosis, with Phase 3 trials for pneumoconiosis. It also has F573 in Phase 2 for acute liver failure; preclinical F230 for pulmonary arterial hypertension and F528 for COPD. Founded 2002 as a subsidiary of GNI USA.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Ying Luo Ph.D.
- Founded2002
- Employees625
- Websitewww.gyretx.com
Identifiers
- ISINUS4037831033
- FIGIBBG000F88SY8
- CUSIP403783103
- CIK0001124105